## 2020/21 IMPACT Report & Accounts
Breast Cancer UK Ltd Charity No. 1138866 | Company No. 7348408
1
## Contents
About Breast Cancer UK ......................................................................................................................... 3 Our charitable objectives ....................................................................................................................... 3 Our approach to prevention: ................................................................................................................. 3 Our guiding principles: ........................................................................................................................... 3 A word from the Chair and CEO ............................................................................................................. 4 Working towards our strategic goals to prevent Breast Cancer ........................................................... 6 Overview of the year (April 2020 to March 2021) ................................................................................. 9 Trustee Report: Our Activities and Achievements .............................................................................. 10 The Science Programme ...................................................................................................................... 10 Bringing scientific information into the public arena .......................................................................... 15 Future plans for the Science Programme ............................................................................................ 15 Our Education Programme .................................................................................................................. 16 A new breast check video .................................................................................................................... 17 Future plans for our educational programme ..................................................................................... 17 Our generous supporters ..................................................................................................................... 18 Our donors and fundraisers ................................................................................................................. 18 Philanthropy, corporate partners and legacies ................................................................................... 20 Our Advocacy programme ................................................................................................................... 21 UK Advocacy, Campaigning, and Impact ............................................................................................. 21 Future Plans for our advocacy and public affairs programme ............................................................ 23 Financial Review ................................................................................................................................... 25 Principal funding sources ..................................................................................................................... 25 Charitable Expenditure ........................................................................................................................ 25 Reserves policy ..................................................................................................................................... 26 Results and closing position ................................................................................................................. 27 Structure Governance and Management ............................................................................................ 28 Structure .............................................................................................................................................. 28 Governance .......................................................................................................................................... 28 Staff ...................................................................................................................................................... 29 Risk Management ................................................................................................................................ 29 Statement of public benefit ................................................................................................................. 29 Statement of Trustees Responsibilities for the Year Ended 31 March 2021 ....................................... 31
2
## About Breast Cancer UK
Around 56,000 women and 370 men in the UK are diagnosed with breast cancer every year and it is predicted that 1 in 7 women will get breast cancer at some point in their lives. Yet over a quarter of breast cancers are preventable.
Making simple changes to diet and lifestyle, and avoiding certain chemicals, can reduce many people’s risk. Breast Cancer UK’s mission is to reduce the incidences of breast cancer that are preventable through scientific understanding, education, collaboration and policy change.
## **Our charitable objectives**
1. to advance health and save lives by encouraging a preventative approach to breast cancer
2. to educate and raise awareness of the preventable risk factors for breast cancer and provide practical information to help people reduce their risk; and
3. to support scientific research that helps us to understand and address the preventable risk factors for breast cancer.
## **Our approach to prevention:**
**Science:** We support scientific research that helps us to understand and address the preventable risk factors for breast cancer.
**Education:** We educate and raise awareness of the preventable risk factors for breast cancer and provide practical information to help people reduce their risk.
**Advocacy:** We campaign for policies that support the prevention of breast cancer.
## **Our guiding principles:**
**Breast Cancer UK believes prevention is possible:** more can be done to prevent breast cancers by tackling lifestyle and environmental risk factors.
**We are evidence based:** scientific evidence is at the heart of our work with sources clearly identified.
**We champion high environmental and ethical standards:** partnering with companies and suppliers whose own ethical and environmental policies match these standards.
**We believe in the right to know :** we want to empower people by giving them the information they need about the preventable risk factors for breast cancer, so they can make informed choices. **We believe in collaboration:** we will actively identify, seek and establish collaborations with other stakeholders (e.g. charities, think tanks, companies, government and scientific institutions) to ensure we are effective in delivering our goals.
3
## A word from the Chair and CEO
We are pleased to present our Impact Report and Accounts for FY2021. This unprecedented year started with the uncertainty brought about by the shock of a global pandemic but our investment in digital transformation enabled us to close the year with a growing base of valuable supporters, financial stability, clear direction and a stronger than ever resolve to achieve our mission to prevent breast cancer.
The immediate financial and operational impacts of the pandemic meant we sadly had to take swift and difficult decisions to stabilise and sustain the charity, our work and our team. In the first six months of the year, we furloughed 75% of staff and implemented a cost-saving downsizing of the team. These measures were necessary to minimise the impact of the pandemic on our cause but it meant we had to come up with innovative ways to continue to deliver our programme of work.
Effects of the pandemic were felt across our operations from our scientific research programme which saw scientists unable to carry out lab work, to our ambassadors who could no longer offer face-to-face prevention talks. The pandemic also highlighted the urgency of breast cancer prevention in the face of the significant delays people experienced in accessing breast cancer diagnosis and treatment services.
We responded by sharpening our focus and immediately progressed our digital transformation to build on the recent launch of our new website. We saw the opportunity to bring our vital prevention education online through a digital learning experience that would be both bespoke and accessible to a wider and more diverse audience. We were, therefore, thrilled to be awarded a £50,000 grant by the Ecclesiastical Movement for Good who shared our belief and saw the huge potential digital channels have in growing our community of prevention activists and ultimately reducing incidences of breast cancer in the future.
The uncertainty of the pandemic has shown the resilience and adaptability of our charity. It has underlined our strength of purpose as we continued our efforts to understand the links between exposure to environmental chemicals and breast cancer risk by supporting our researchers to return to the labs safely ensuring they were given additional time to pick up the work they had been forced to delay. We also continued our work to bring evidence to the attention of policymakers maintaining engagement and advocating for vital public health protection in the post-Brexit UK Chemicals regime.
Our donors and fundraisers also rose to the challenge of the pandemic, responding to our urgent appeals and raising more money than ever for our charity. None of our work would be possible without their generosity and commitment to our breast cancer prevention work. We thank them wholeheartedly for supporting us and believing in our cause.
4
Our highly committed Board of Trustees were also instrumental in putting their varied skills into action by offering solid stewardship and guidance to the team throughout the crisis. They continue to generously contribute significant expertise in the areas of human resources, accountancy and strategic planning. After four and a half years serving as Trustee and a further 18 months as Chair, Mary Davies stepped down in December 2020. Mary’s parting legacy is a charity that operates mature governance policies and processes. As an economist and strategist, Mary led the board with precision and inclusion, carefully balancing risks over benefits and ensuring that our charitable purpose remained at the heart of all decisions. We thank Mary for her contributions and commitment and wish her well in her future ventures.
Trustees unanimously supported the appointment of Wendy Clark as new Chair of the Board in December 2020. A trustee since June 2018, Wendy brings senior management experience in public health digital technology and is passionate about supporting our charity’s digital transformation to take our breast cancer prevention education experiences to a wide and diverse audience. We also welcomed three new trustees Mark Jarvis, Sharon Nash and Margot Black who brought much needed skills in financial planning, HR and fundraising respectively. We would like to thank all the trustees for their time and effort and commitment to the cause.
Our dedicated staff rose to the year’s immense challenges, working tirelessly to keep our mission on track to support world class scientific research, bring high quality information to people across the country and drive public policy change that improves health protections. We thank them for their continuing dedication, their creativity and hard work.
Wendy Clark Thalie Martini Chair CEO
5
## Working towards our strategic goals to prevent breast cancer
This year we continued to expand our strategic aim to tackle all modifiable risk factors of breast cancer. We did this by enhancing our awareness raising efforts and our commitment to providing high quality scientifically evidenced information and advice on lifestyle risk factors and environmental and chemical risk factors for breast cancer. We engaged a wider and larger audience, with accessible inclusive messaging helping more people understand what steps they can take to actively reduce their risk of breast cancer.
We successfully launched our “25 saves lives” prevention awareness campaign during Breast Cancer Awareness Month (BCAM) highlighting the benefits of regular physical activity and exercise in reducing breast cancer risk whilst challenging people to get moving, take charge of their health and make regular physical activity a part of their daily routine.
The shift in our awareness and education work to encompass lifestyle risk factors of breast cancer means that Breast Cancer UK is now the only breast cancer charity in the UK working to tackle all risks including environmental and chemical risks of breast cancer.
Our strategic goals underpin our approach to prevention in the following three ways:
**1. We support scientific research that helps to understand and address the preventable risk factors for breast cancer.**
Our advice and information on lifestyle risk factors for breast cancer are informed by the breadth of existing research linking factors such as poor diet, weight gain and alcohol consumption to breast cancer risk. This year, our scientific investment in research remained focused on understanding the impact of Endocrine Disrupting Chemicals (EDCs) on breast cancer risk. This is a continued bid to bridge the gap in understanding of how these complex chemicals exert their effects on health and specifically on our breast cancer risk.
Despite the hiatus imposed on our scientists, we ensured that our scientists were supported throughout the pandemic by providing extensions and additional financial support where it was needed to minimise the disruption to their lives and their vital research. Fostering and building a strong community of scientists and researchers interested in breast cancer prevention is one of our investment priorities alongside supporting innovation and effectiveness in research.
Our efforts to innovate alongside the support of our donors and supporters means that our plans will involve expanding our scientific research programme.
6
**2. We educate and raise awareness of the preventable risk factors for breast cancer and provide practical information to help people reduce their risk**
This year we innovated our awareness and education in the face of unprecedented uncertainty. We recognised that to reach more people, we needed to improve our digital offer, diversify our content to be more responsive to the needs of the many different audiences whose lives our work can positively benefit including younger people and people from different walks of life.
We wanted to simplify accessing information and putting prevention into practice. We built a strong proposition for support which yielded generous donations from supporters and the Ecclesiastical Movement for Good. Empowering individuals and working collaboratively to increase awareness, we believe, will help us reduce the number of breast cancer cases diagnosed every year.
**3. We campaign for policies that support the prevention of breast cancer**
While we can all take individual action to reduce our risk, national and local policies that promote healthier environments and facilitate access to preventative health advice is key to achieving long term health benefits across the country. We continued our efforts to call for cancer and health strategies to put prevention first and acknowledge a broad range of risk factors including the links between harmful chemicals and the risk of diseases such as breast cancer.
Our efforts to advocate for breast cancer prevention policy and health protections were significantly hindered by the pandemic both in terms of our internal resourcing but also due to public resourcing being diverted to cope with the health crisis. This alongside the departure of the UK from the EU meant that our ability to engage with government officials and policymakers was reduced. We shifted our efforts towards collaborating with other UK based organisations who share our concerns and our vision to improve health protections and promote a precautionary approach to environmental risk factors such as EDCs.
The success of these new alliances has now set the tone for a continued collaborative approach towards mobilising policymakers and the public to demand policies addressing the potential harms environmental chemicals such as EDCs pose to our health and breast cancer risk.
7
## **1. Science and Research**
Our priorities are:
- Funding high quality scientific research on the potential consequences of exposure to low dose environmental chemicals.
- Working to identify and address data gaps in our understanding of risk and causation.
- Collating and sharing new data to understand the potential links between harmful chemicals and breast cancer.
- Strengthening our independent scientific research panel, to ensure our advice, data and research is of the highest quality.
- Bringing together a network of researchers and experts in the field of breast cancer prevention to promote understanding about the prevention and causation of breast cancer.
## **2. Education and Awareness**
Our priorities are:
- Digitising our education and awareness to offer a more accessible engaging experience to a wider audience across the UK.
- Continuing to grow the breadth of information and advice on our website and via social media on all modifiable risk factors for breast cancer and how these apply to different population groups.
- Carrying out audience insight research to understand their needs and behaviours, inform our work and ensure we reach an ever-wider audience.
- Working with a wide range of organisations, companies, charities and individuals to ensure our messages are reaching those who need them most.
## **3. Advocating for Policy Change**
Our priorities are:
- Working with a wide range of policymakers and scientific experts to help identify practical policies that promote the primary prevention of breast cancer.
- Empowering and enabling our supporters to speak out in support of a preventative approach.
- Generating campaigns that promote the primary prevention of breast cancer.
- Building meaningful collaborations that help us to secure change for the better.
- Campaigning for policies, laws and regulations that protect and improve our health and that of the environment.
- Supporting policies that promote the precautionary principle and prioritise the protection of human health.
- Working with others to cofund research into prevention and causation of breast cancer.
8
## Overview of the year (April 2020 to March 2021)
||• Dr Laura Matthews’ grant was completed: “Identifying nuclear receptor disruptors||
|---|---|---|
|Quarter 1|as risk factors in breast cancer”project summary
• LaunchedGo Bald fundraising campaign,which raised £46,865.21||
||• Met with Shadow Charities Minister Rachael Maskell MP to highlight BCUK calls to||
|April to|action.||
|June|||
||• Launched Putt for Prevention campaign||
|Quarter 2|• Launched ‘25 Saves Lives’ BCAM awareness campaign –Supporting more people to
take up regular physical activity||
||• We rebooted our education webinar and delivered to communities across UK on-||
|July to|line||
|September|||
||• Launched our new breast check video and text reminder service. By the end of the||
|Quarter 3|year, we had over 18,000 views and 700 signups to our text reminder service.
• Secured £50,000 from Ecclesiastical Movement for Good Awards for development||
||of Prevention Hub||
|October to|• Launched the BCUK GEMS programme to nurture and build our community of||
|December|supporters and regular givers.
• Formed NGO coalition on harmful chemicals to advocate for legislation that||
||protects thepublic from environmental chemicals harmful to health.||
||• Launchedof new scientific research grant round; up to £100,000 available per||
|Quarter 4|project
• Launched Push for Prevention fundraising campaign||
||• Joined Public Health and Environmental NGOs in deliveringrebuttals to industry||
|January to|proposals to deregulate the UK Chemicals regime, March 2021. Our calls were||
|March|covered in theFinancial Times and Ends Report.||
9
## Trustee Report: Our Activities and Achievements
## **The Science Programme**
## **Our objectives were to:**
- Support high quality, independent scientific research projects at universities or research institutes within the UK
- Bring relevant, high-quality data and new research findings into the public arena, and
- Grow our scientific expertise and reputation in the field of breast cancer prevention.
Breast Cancer UK funds scientific research projects which explore the link between breast cancer and potentially harmful chemicals found in everyday products and the environment. While there is evidence to show that lifestyle factors such as alcohol consumption and obesity can influence breast cancer, there is less research on the effects of environmental chemicals on breast cancer risk. Our grants programme aims to help fill the gap in our knowledge and understanding of this area of breast cancer risk.
## **Breast Cancer UK’s Grant Funding Programme**
Since the launch of our grants funding programme in 2015, we have allocated over £265,000 worth of grants to independent scientific research. During the FY2020/21 we supported three ongoing research projects, one new project and one which came to completion. The Covid-19 pandemic caused serious disruption to laboratory research. As a result, all our funded projects were disrupted, resulting in delays to their completion dates as well as delays to the start dates for new projects.
## **Research projects**
We currently co-fund two PhD studentships, which began in October 2018 and were due to finish at the end of September 2021. As a result of the disruption caused by the pandemic, we have granted a 3-month extension to both students.
One of the studentships was awarded to **Professor Valerie Speirs** from the University of Aberdeen, and her student, **Ms Kerri Palmer** . The project is co-funded by the charity **Animal Free Research UK** and examines the effects of endocrine disrupting chemicals on breast density.
The aim is to understand whether certain chemical exposures can lead to a high breast density - which is a significant risk factor for breast cancer. The research also aims to develop animal free research methods and uses a pioneering 3D breast cell culture system.
To understand the impact of chemicals on humans, we believe using human breast tissue, rather than animal models, is necessary. Despite the considerable interruption to laboratory work, progress was made during the year (see “The impact of Covid-19 on laboratory research” below).
The other PhD studentship was awarded to **Dr James Thorne** and his student, **Mr Alex Websdale** , from the University of Leeds. Alex’s studentship is co-funded by the **University of Leeds** . The project investigates the role of oxysterols in promoting triple negative breast cancer progression. The project has
10
progressed well and has already generated two peer reviewed research papers (see Research highlights below).
**Dr Michael Antoniou** along with **Dr Robin Mesnage** from King’s College London are investigating the cancer-causing potential of bisphenol combinations in breast cells. Bisphenol substitutes are being increasingly used to replace bisphenol A (BPA), which is a substance of very high concern due to its endocrine disrupting properties. This work was due to be completed in early 2021, but final laboratory experiments were delayed because of the pandemic and the project will now be completed by the end of 2021. We look forward to hearing about the results of this project.
In November 2019, we awarded a grant of £43,360 to **Dr Elisabete Silva** , from the University of Brunel London, to examine the impact of mixtures of endocrine disrupting chemicals and saturated fats (that may result from a high fat diet) on the early stages of breast cancer. The project uses an exciting new threedimensional breast cancer model system known as “Breast-on-chip”. This method of culturing different types of breast cells more closely mimics how breast cells behave in the body. The project was due to begin in early 2020, but due to the disruption caused by the pandemic, it did not start until January 2021. We look forward to the results of this innovative project.
Research carried out by **Dr Laura Matthews** , from the University of Leeds, was completed in August 2020. Her work investigated which nuclear receptors play a role in breast cancer and which environmental chemicals can disrupt these receptors and so affect breast cancer risk. Nuclear receptors are cellular proteins which regulate diverse functions such as reproduction, cell multiplication and metabolism.
Dr Matthews’ study compared nuclear receptor activity in normal breast tissue and different types of breast cancer tissue. Seven nuclear receptors which play a role in triple negative breast cancer were identified. Using pre-existing datasets, 200 chemicals were identified that are predicted to alter nuclear receptor activity in a similar way to changes seen in triple negative breast cancer. Many of these chemicals, including pesticides and disinfectants, increased breast cell multiplication, and so may increase breast cancer risk.
Environmental chemicals that potentially drive breast cancer development may therefore be identified using nuclear receptor expression profiles. Breast Cancer UK was delighted to learn that Dr Matthews’ BCUK-funded research was selected by the Society for Endocrinology as being of potential interest to the worldwide media and the society released a press statement, as mentioned in our previous annual report. A link to her final report can be found here.
## **Grant funding application round**
A new grant funding round was launched in January 2021. Awards will be announced in September 2021. Thanks to the continuing support of our donors, we were able to increase the maximum funds available for a single project to £100,000 from a previous maximum of £45,000. This is extremely positive as the increase enables BCUK to fund longer term projects and fully support PhD studentships.
11
Grants will be awarded for research into the effects of bisphenols on breast cancer risk. We chose this as a priority area of funding for several reasons. It builds on our earlier work which campaigned successfully for a ban on bisphenol A in baby bottles, and for a ban on its use in everyday plastic products.
Bisphenol A (BPA) was identified by the EU as a substance of very high concern in 2017 and is now banned for use in thermal paper. Although it is being phased out of many everyday products it is being replaced by other types of bisphenols such as BPS and BPZ.
Research, including recent work funded by us, suggests these bisphenol substitutes may also affect breast cancer risk. This research is timely as it will help build stronger evidence in support of our campaigning for a ban on the use of BPA and bisphenol substitutes in food contact materials, a ban on the use of bisphenols substitutes in products where BPA was used previously, and for bisphenol substitutes to be treated as a single grouping with regards to chemicals regulations.
## **About Our Grant Programme**
Breast Cancer UK is committed to funding high quality research that will help us to better understand the causes and risk factors for breast cancer. To ensure we only fund research of the highest quality, we have a rigorous grant application process.
- We typically have one grant funding round each year.
- We do not fund research that involves animal testing.
- We only fund projects that are ethically approved.
- We have very clear application criteria and only fund research into breast cancer prevention.
- We prioritise research that helps us to understand the link between environmental chemicals and breast cancer.
- All grant applications are peer reviewed by two members of our Independent Scientific Panel or an expert in the relevant field.
- The Panel members review the applications based on merit.
- The Panel includes independent experts in the field of oncology, public health, endocrinology, epidemiology, toxicology and other biological sciences.
- Successful grant applicants must abide by certain criteria - failure to do so could result in a grant being withdrawn.
- The Science Committee makes the final decision on which applications will receive an award. The Committee includes Trustees with a scientific and research background and our Head of Science, who is a former research scientist.
## **Independent Scientific Review panel**
Breast Cancer UK’s Independent Scientific Review Panel was established in September 2016 to help strengthen our science and grant funding program by providing expert scientific advice, specialist knowledge and expertise to staff and Trustees on subjects and themes relating to the various risk factors for breast cancer, including the links associated with exposure to harmful chemicals and those associated with diet and lifestyle.
Panel members independently peer review all grant applications and the organisation’s body of scientific literature to ensure it is of a good scientific standard, meets Information Standard criteria and is based on sound scientific principles. The panel currently comprises 17 members, all independent scientists or clinicians. Details of panel members.
12
## **Research Funding Impact**
**Research Project:** Oxysterols as functional biomarkers of Triple Negative Breast Cancer relapse **Award** : £45,000 to Dr James Thorne (University of Leeds) and Dr Hanne Røberg-Larsen (University of Oslo) PhD studentship: Mr Alex Websdale (University of Leeds)
The project aims to investigate the role of oxysterols in triple negative breast cancer. Oxysterols are chemicals thought to be associated with increased risk, recurrence and spread of breast cancer. They are produced in the body from the breakdown of cholesterol. They may also enter the body following consumption of certain types of food, for example, meat cooked at high temperatures.
Patients with breast tumours that are negative for oestrogen, progesterone and HER2 receptors (known as triple negative breast cancer) typically have a worse prognosis than patients with other subtypes. Targeted therapies such as Tamoxifen or Herceptin do not work, so these patients often have chemotherapy treatments with more severe side effects.
Alex’s results show cholesterol is modified by enzymes in breast tumours to produce specific types of oxysterols that cause hormone receptor-negative breast cancers to become resistant to chemotherapy. The presence of particular oxysterols and enzymes that produce them may therefore be useful indicators of whether a patient is going to suffer a breast cancer recurrence.
These results formed part of a publication in the prestigious journal Oncogene, which examined the link between chemotherapy resistance and cholesterol metabolism. Through a series of cell and molecular biology experiments, Alex and co-authors found that chemotherapy drugs were more likely to be exported from triple negative breast cancer cells that had previously been exposed to a specific class of oxysterol. Alex was the joint first author and James corresponding author. The paper was highlighted in a Nature portfolio Cancer community Behind the paper article.
During the lockdown, Alex carried out a literature review, which formed part of a meta-analysis published in Critical Reviews in Food Science and Nutrition. The review focused on the role of phytosterols and phytostanols in cancer. He also attended the British Association for Cancer virtual student conference 2021 in February 2021. We were delighted to learn that Alex was awarded the BACR executive committee poster prize for his poster "24-hydroxycholesterol promotes chemoresistance through enhanced expression of P-glycoprotein", based on his PhD work. You can read more about Alex’s work here
13
## **2020 – A challenging yet productive year for our research**
Below is an abridged version of Professor Speirs thoughts on the impact of Covid-19 on her PhD student’s research during 2020.
While 2020 brought us many unexpected challenges, it also brought exciting developments. We identified new techniques that will improve investigations of bisphenols (chemicals found in certain plastics) and we identified crucial genes and cellular pathways within the breast that are altered by bisphenols, and which may promote breast cancer development.
## **A positive start to the New Year**
After the Christmas holidays, Kerri Palmer and I returned to work to discover that we had a short letter accepted for publication in the prestigious medical journal, The Lancet Diabetes and Endocrinology. In it we challenged the reliability of the method being used to determine the level of bisphenol A (BPA) exposure in humans. We believe that it underestimates just how much BPA is present in the environment. Kerri continued to investigate the stability of bisphenol compounds, including BPA, which was once common in many household items like plastic bottles, can linings, and paper receipts. BPA may leach from these objects and be absorbed into the body where it mimics oestrogen and harms our health, including breast cancer risk. Kerri’s PhD focuses on investigating this in detail.
## **Springtime lockdown**
Kerri, with help from undergraduate project students she is co-supervising, hopes to identify optimum laboratory storage conditions for BPA, which will improve the accuracy of experiments involving these chemicals. Kerri is very excited to see what results she can obtain in her final year, to expand current knowledge of how bisphenols may be accurately measured in the laboratory.
By March, the lockdown meant all university research laboratories were closed. Before this, Kerri had already started computer-based analyses, which meant she could continue with this work full-time. The analyses would include identifying crucial genes and cellular pathways within the breast that may be changed by BPA and may promote breast cancer development. These findings would go on to form the basis of Kerri’s first experiments once laboratories could reopen.
## **Summer’s ray of light**
The July sunshine brought a ray of light as access to laboratories was regained, bringing with it a hint of normality. As numbers were strictly capped, shift working had to be implemented. Despite this, Kerri managed to complete some initial experiments resulting from her computer-generated work. She also started work to create an animal-free 3D model of the breast, using human cells. This model is just like a normal breast structure. Kerri will use this model and other techniques to identify changes to breast cells that occur upon BPA exposure. This will help us to understand how BPA affects the normal breast, and how it contributes to the promotion of breast cancer.
## **Autumn leaves more exciting news**
Kerri’s work on bisphenol stability experiments continued and proved much more complex than anticipated. By the autumn, she was in the process of a long-term experiment to identify how certain storage conditions affect bisphenol concentrations, as this could affect experimental results.
## **Winter – the end of a challenging yet exciting year**
It’s fair to say that 2020 threw many challenges Kerri’s way. She has done a great job adapting to them and is determined to work hard in the final year of her PhD. She hopes to produce some interesting findings and to contribute new knowledge to the wider scientific community about bisphenol A, its uses in the laboratory and exactly how it may be contributing to breast cancer development.
## **Professor Val Speirs**
14
## **Bringing scientific information into the public arena**
As well as producing research-based publications, leaflets, and content on our website and social media, Breast Cancer UK believes it’s important to help people make sense of the often complex and sometimes contradictory scientific information before them. This year we have continued to provide plain English guides to the science behind our message on prevention. New scientific content written in plain English has featured in our iGuides, which is part of our new Prevention Hub.
We began a new “Meet the Scientist” series, which features interviews with our grant holders who explain the background to their research. This series featured Professor Val Speirs, Dr Elisabete Silva, Ms Kerri Palmer and Dr Laura Matthews’ PhD student Ms Freya Leif.
To provide more comprehensive information for those with a scientific background, we released scientific briefings on Physical Activity and Breast Cancer, and on Nutrition and Breast Cancer. These were generated using our Information Production Process, which includes evaluation by two members of our Independent Scientific review panel.
We also posted a webinar on the role of physical activity in helping to prevent breast cancer, which explains the science behind why physical activity is beneficial. We also hope it helps motivate individuals to become more active to reduce their risk of breast cancer as well as many other illnesses.
Our science blogs are also intended to provide easy to read information about the science behind breast cancer risk and prevention. As part of BCAM 2020, we included a blog on our top 25 tips to reduce your risk, and as part of Pesticide Action Week, our panel member and funded researcher Dr Robin Mesnage wrote a blog for us about pesticides and breast cancer.
## **Plans for the Science Programme**
In 2018 Breast Cancer UK organised the first ever UK Round Table meeting on breast cancer prevention hosted by **Professor Philippa Darbre** at the University of Reading. Plans were in place to host two follow-up meetings in 2020 hosted by University of Leeds grant recipients’ **Dr James Thorne** and **Dr Laura Matthews** . The aim of the first meeting, planned for March was to generate a multi-authored journal article on breast cancer prevention, which highlighted significant research gaps. The second meeting planned for September was an academic scientific conference on breast cancer prevention, open to all. Unfortunately, due to the pandemic, both meetings were cancelled and the Leeds researchers are no longer able to host such a meeting. We hope to organise a Breast Cancer Prevention meeting in the next financial year.
In future, we plan to continue to grow our grant programme increasing the number and value of grants that we can fund. We will also strengthen our literature associated with nutrition and breast cancer by investigating and writing about the impact of vitamin D on breast cancer to find evidence of whether vitamin D supplements may reduce risk. We will also investigate the role of fibre and microorganisms in breast cancer risk. We will update our literature on bisphenol A and publish a new brief on bisphenol substitutes, which will support our future campaigns. We plan to commission a brief gathering evidence on
15
the protective factors of breastfeeding and breast cancer. And finally, we plan to highlight male breast cancer, including an update of our existing brief as well as new information about breast cancer on our prevention HUB (as mentioned elsewhere).
## Our Education Programme
## **Our objectives were to:**
- Develop educational advice for members of the public who want to know more about lifestyle and environmental risk factors for breast cancer
- Improve access to practical solutions that help people take direct action to reduce their risk
- Reach and engage more young women with our message
- Grow and consolidate our ambassador programme so that we help more people understand how to reduce their risk.
In the last year, we have continued to build on the versatility and reach of our new website. We intensified our efforts towards innovative and varied content output through blogs, breast cancer stories, video and live events.
In October 2020, we successfully launched our ’25 saves lives’ campaign for Breast Cancer Awareness Month. Our signature campaign, which centres around the risk reducing benefits of exercise and physical activity, raises awareness that over 25% of breast cancer cases are preventable through lifestyle changes such as regular physical activity.
We developed new partnerships with like-minded fitness organisations and corporates to deliver free online Pilates sessions and an online fitness festival aimed at motivating supporters to build physical activity into their everyday lives. This multifaceted approach has enabled us to grow our supporters and
16
prevention community, reaching new audiences to help them understand and take action to reduce their risk.
The unforeseen impact of the pandemic on our charity and services has led us to rethink how we communicate our prevention education and how we motivate audiences to put prevention first. High quality, inclusive visual content and learning experiences tailored to the individual lives of a broad section of people was our vision.
A key part of our digital transformation, we took this idea to the Ecclesiastical Movement for Good who believed in our vision and generously awarded the project a £50,000 grant over three years. We are very excited to have set in motion a highly innovative experience aimed at making our prevention education straightforward and accessible to a wide audience from all walks of life.
## **A new breast check video**
Designed to give a simple snapshot of what to look for and how to check your breasts, the ‘know your breast’ video was launched for Breast Cancer Awareness Month in October 2020 as a visual guide for women and men all over the country.
We developed this resource in response to supporters telling us that simple information on understanding and checking your breasts is important to women and men as part of their prevention action.
To support people, we also launched a text reminder service users can sign up for, that sends a text reminder each month to check their breasts.
## **Plans for our educational programme**
We have plans to launch our Prevention Hub in summer 2021 to mark Breast Cancer UK’s 20[th] Anniversary. We will continue to add new elements to this unique online learning experience. We also plan to work more closely with other health, breast cancer and like-minded organisation to share this important information far and wide to ensure everyone has the opportunity to reduce their risk of developing breast cancer. We will continue to produce a variety of engaging information and content on breast cancer prevention in the form of stories, videos, live events and much more ensuring Breast Cancer UK is the onestop breast cancer prevention community.
17
## Our generous supporters
## **Our donors and fundraisers**
COVID prevented people from engaging in their usual events and activities. However, it did not stop them from believing in our cause and finding new and creative ways to support our work and for that, we are incredibly grateful. From the outset of the pandemic, supporters dug deep, giving to our COVID emergency appeal in whatever way they could. From donating directly to taking part in challenges at home, our supporters raised more than ever to keep our vital work going. To show our gratitude for our amazing supporters, we launched our Donation Wall.
We thank them all for sharing our passion and determination to reduce the suffering and devastation caused by breast cancer and to ensure fewer people receive a devasting diagnosis in the future. Below is a snapshot of the incredible achievements and dedication of our fundraisers.
We thank **the Jeffries family and their friends** for their incredible effort raising over £15,000 through a hugely successful head shave challenge in support and affection for Josey Jeffries.
18
We thank the **Finkle Street businesses** for rallying together to support loved ones through the ‘Great Finkle Street’ shave and collectively raising £5,900 for Breast Cancer UK.
We thank **Kirstin McCord and fiancé Jordan** who walked a million steps in one month and raised over £4,500 in support of Kirstin’s sister all the while helping remind women to check their breasts regularly.
We thank the team at **S&P One Commercial EMEA** – who turned their walking and cycling challenge into a disco extravaganza for Breast Cancer UK raising over £2,800.
19
We thank **Malcolm Swarbrick** who battled the unpredictable weather and successfully swam the English Channel solo raising over £3,300 for our cause.
We thank **Martin Holt and his brother Andrew** who put on the most incredible Christmas light show to bring cheer to his neighbourhood and all of us at Breast Cancer UK raising over £4,300.
##
##
We were thrilled to partner with Boody who sponsored our BCAM campaign and beyond. We were equally excited to be offered a grant of £50,000 from the Ecclesiastical Movement for Good to help advance our digital transformation in education through the development of our new prevention hub. Finally, this year we were grateful to receive £111,000 from generous gifts left to our charity in Wills.
20
## Our Advocacy programme
## **Our objectives for the last year were to:**
1. Encourage a preventative approach by campaigning to improve legislation and public health policy which helps to promote the primary prevention of breast cancer.
2. Work at both EU and UK levels for policy and regulatory changes that help to protect against breast cancer.
3. Raise the profile of our key messages amongst political decision makers by establishing a network of activists to help us make our message heard.
This year, Breast Cancer UK’s advocacy work has focused on campaigning for improved public health and environmental protection from harmful chemicals with links to increased breast cancer risk. We have sought to help shape policymaking in the UK and EU, to improve consumer protections, promote cancer prevention policies and retain a precautionary approach to prevent breast cancer.
## **UK Advocacy, Campaigning, and Impact**
Our public affairs work focused on lobbying for improvements in legislation and public health policy to reduce public exposure to harmful chemicals linked to increased breast cancer risk. This includes exposure to chemicals that are either carcinogenic or endocrine (hormone) disrupting chemicals found in everyday products and the environment.
Over the past year, we sought new opportunities to engage with ministers and government officials to outline the need to strengthen public protection from harmful chemicals linked to breast cancer. We continued to participate in the policymaking process by attending meetings, responding to relevant consultations, inquiries, and green papers with new proposals to influence the UK policymaking process.
This we achieved despite our reduced capacity due to furloughing of staff, the uncertainty of Brexit over the future of UK chemicals regulation and the Covid pandemic impacting our ability to directly engage with key people to influence UK Chemicals and cancer policy.
## **The Impact of Brexit on Chemical Protections**
Following the UK’s EU departure, the future of public protections from harmful chemicals remains uncertain. With the new UK Chemicals regime ‘UK REACH’ (Registration, Evaluation, Authorisation and Restriction of Chemicals) coming into force in January 2021, we are operating within a new policy environment where EU protections no longer apply, as the UK takes responsibility for regulating chemicals. The EU is considered the ‘gold standard’ of chemicals regulation, yet the UK is at risk of falling behind EU “ ” protections, despite this, the UK government has committed to not diverge for divergence sake .
In March 2021, the UK announced its new restrictions programme for the first year of UK REACH. Restrictions are a way of banning or controlling a substance that poses a risk to human health and the environment. This programme confirmed that the UK would match two of the EU’s 13 proposed restrictions. Since January, the UK has failed to keep up with the EU on its candidate list for identifying
21
substances of very high concern with the EU adding 10 additional substances including brominated flame retardants and EDCs linked to breast cancer. This is the first example of the UK falling behind EU chemicals controls.
Breast Cancer UK’s concern is that the UK runs the risk of becoming a dumping ground for harmful chemicals banned at the EU level in the years to come. With this concern in mind, we actively engaged with government officials and collaborated with public health and environmental NGOs to ensure the hard won public health and environmental protections are maintained and enhanced post-Brexit.
## **UK Public Health Policy**
The focus of public health policy this year has been to respond to the impact of Covid-19 on the NHS and deal with the cancer backlog. Since the start of the pandemic, over 40,000 fewer cancer patients received treatment with an estimated 11,000 people living with undiagnosed breast cancer. We highlighted the need to put prevention first by prioritising action to address lifestyle and environmental risk factors.
As campaigners for the primary prevention of breast cancer, we were encouraged to see public health policy beginning to prioritise prevention through the prevention green paper and the new responsibilities of public health bodies. Disappointingly, public health plans fail to give attention to the effects of harmful chemicals. We continued to call on the government to recognise the public health risks of exposure to harmful chemicals and recognise them as preventable risk factors within public health plans.
In August 2020, the government announced plans to disband Public Health England and transfer its responsibilities to two new public health bodies the UK Health Security Agency and the Office for Health Promotion. We sought to engage with public health officials to ensure these bodies are given responsibilities to monitor, research and regulate the effects of harmful chemicals on the nation’s health.
As always we maintained our commitment to speaking up for and underline the urgency of prevention. We are the only UK breast cancer charity advocating for a greater focus on prevention by addressing exposure to harmful chemicals in everyday products and the environment.
## **Public Affairs Initiatives**
In April 2020, we engaged with the Minister for Civil Society Baroness Barron and provided a submission to the Digital, Culture, Media and Sport select committee. We outlined the significant effect Covid-19 had on our fundraising activities, research programmes and our community education outreach.
In October 2020, we joined Public Health and Environmental NGO’s in writing to George Eustice to express our concerns about UK preparations for a proposed GB REACH chemicals regime and the implications for public protection from harmful chemicals. Following this intervention, the government committed to extending timetables to transfer data on chemical substances into the UK to ensure regulators have access to safety information on chemicals to act in circumstances where they pose a risk to human health and the environment.
In November 2020, we co-authored a joint letter signed by 15 signatories to Secretary of State Matt Hancock calling for the new public health bodies to be given explicit responsibilities to monitor, research and regulate the effects of harmful chemicals on the nation’s health. We continue to campaign for these public health bodies to recognise exposure to harmful chemicals as a cancer risk factor.
In December 2020, we submitted policy proposals to DEFRA on proposed provisions for the authorisation and restriction of chemicals and stakeholder engagement under the post-Brexit UK chemicals regime. We
22
called for the UK to align with the EU to protect public health and deliver, safer consumer products, healthier foods and a cleaner environment.
In January 2021, we co-signed a joint letter to the Prime Minister on the Trade Bill alongside Greener UK, Client Earth, CHEM Trust calling on the Government to ensure that arrangements are in place to ensure the effective scrutiny of future trade deals and for the UK to show leadership in putting public protections at the heart of its trade policy.
In February 2021, we provided detailed policy proposals in response to the draft national action plan on pesticides. We called for the government to introduce pesticide reduction targets and to give public health bodies direct responsibilities to monitor and recommend restrictions on chemicals of concern to protect the nation’s health.
In March 2021, we co-authored a joint letter to UK government Secretaries of state to issue rebuttals to industry proposals to deregulate the UK Chemicals regime. We called on the Government to deliver on the founding principles of REACH which include ‘no data, no market’, minimising animal testing and delivering a high level of protection for human health. Following this intervention, the government reaffirmed its commitment not to undermine the fundamental principles of REACH.
## **Collaboration**
We continued to attend and actively participate within the UK Chemicals Stakeholder Forum engaging with the Forum initiatives and networking with Government, NGO and industry officials. We became an accredited stakeholder within the Health & Safety Executive as the new UK Chemicals regulator to develop a new working relationship and to influence activities under UK REACH to ensure strong public protections.
In the past year, we increased membership of our UK NGO Working Group on Harmful Chemicals with organisations such as CHEM Trust, Alliance for Cancer Prevention, Cancer Prevention and Education Society, FIDRA, Green Alliance and Marine Conservation Society part of the group. We developed joint initiatives that have strengthened our ability to influence developments within UK Chemicals policy. We joined the Pesticides Collaboration to strengthen our ability to influence pesticides policy developments, post-Brexit.
## **Engagement**
Despite limited opportunities to engage directly with Ministers and Parliamentarians due to the pandemic, we were able to consult with DEFRA’S REACH Team, Chemicals team, Pesticides team, HSE and BEIS officials. We also participated in focus groups on post-Brexit chemicals regulation and presented our key asks for the UK Chemicals Strategy to the Scottish Government and the Northern Ireland Executive.
We wrote to DEFRA Secretary of State, Health Secretary, Business Secretary, Chief Medical Officer and UK Environment Ministers to raise our concerns about the urgent need for action to address public exposure to harmful chemicals and for this to be incorporated within future public health strategies. We halso strengthened engagement in the media with our policy initiatives receiving coverage across several publications.
## **Plans for our advocacy and public affairs programme**
23
We developed a new Public Affairs Strategy to inform our activities over the next three years. Our goals are derived from our charitable objectives and focus on strengthening collaboration, influencing policy and supporter mobilisation.
We intend to strengthen our impact by:
- Building an effective, action orientated alliance with the NGO Working Group on Harmful Chemicals to deliver collaborative and targeted policy and campaign initiatives to achieve stronger public health and environmental protections.
- Positively engaging with government and priority stakeholders to protect the public from exposure to harmful chemicals linked to increased breast cancer risk.
- Launching new public mobilisation campaigns and materials to enable supporters to get our prevention message across to policymakers
We will continually to assess our work, monitor our impact and progress against agreed targets. We will adjust our activities to maximise our impact with the resources we can commit.
24
## Financial Review
The Directors present their report with financial statements of the Company for the period ended 31st March 2021. In preparing this report the Directors have taken advantage of some of the special exemptions applicable to small companies.
## **Principal funding sources**
Total funds raised this year were £666,805. This was a welcome outcome of the charity’s focused effort to adapt to the uncertainty brought about by the pandemic. While our funding potential for the year was largely unknown, the team responded to the crisis by undertaking depth risk assessments, producing pragmatic budget forecasts, reformulating our awareness raising campaigns and producing wider and more engaging appeals for support of our critical prevention work.
These campaigns and appeals succeeded in highlighting the importance of the continuation of our unique prevention proposition which resulted in greater support from the individual members of the public, trusts and foundations and companies for our work.
The largest source of income this year was from Community Fundraising which was made up of Individual Fundraising (£181,014) and Staff Fundraising (£55,225). The next highest sources of income were from individual donations (£137,138) which were made up of In Memory Giving (£77,751) and Individual Giving (£59,387).
In all cases, donations are unsolicited and come from those people affected in some way by breast cancer and who choose to donate or fundraise for our cause. £18,078 was received as restricted donations for scientific research, £16,041 was allocated to the Breast Density project and £2,037 to the Oxysterol project.
This year we also received generous funding grants (£52,500) gratefully received from the Ecclesiastical Movement for Good (£50,000) and Cecil Rosen Charitable Trust (£2,500). Finally, several generous and once again unexpected legacies were also received (£111,751).
We continue to partner with smaller companies and individuals too and would particularly like to thank them for their ongoing support.
## **Charitable Expenditure**
The onset of the pandemic impacted our usual level of spending as concerted efforts were made to reduce costs and overheads as a means of averting financial difficulty and the risk of insolvency. The reduction of staff salaries following the redundancies contributed significantly to the reduction in cost and the stabilisation of the charity’s finances. We spent 75.8% (£304,213) on charitable activities this financial year and 24.2% (£97,314) on raising funds.
This year our largest area of expenditure was on our education programme (£132,325). This reflects our effort to implement a digital transformation of our education programme to reach and engage with a wider and more diverse audience.
Our second largest expenditure was our advocacy programme (£89,161).
25
## **Reserves policy**
## **Purpose of the Reserves**
The charity holds reserves to provide funding to support the continuation of the charitable aims and objectives and the ability to meet financial commitments in the event of a significant unforeseen reduction in income or increase in operational costs.
## **Level of Reserves**
The level of reserves is set by considering the uncertain nature of the charity’s income (which relies entirely on donations, legacies and grants) and the recurrent expenditure and financial commitments the charity has. The charity has limited overheads arising from the accommodation as we do not have a central office space. Hence our main financial commitments and running costs arise from staffing and research grants.
In the event of a significant reduction in income, the trustees believe that six months is an appropriate period in which to seek new income streams to continue the charity’s work or, if these are not available, to reduce staff numbers and costs. These reserves would also allow for the financial implications of any emergency or need to significantly increase operational expenditure.
## **Designated Funds**
The charity is committed to funding research into the chemical and environmental causes of breast cancer. Research grant applications from independent academic institutions are considered periodically and approved at the Board level.
Designated funds represent funds approved by the Board for future spending on research grants and other projects that aim to deliver our charitable objectives. The level of designated funds is updated throughout the year to reflect the amount of funds set aside for future projects until the funds are either committed to a project or a decision is made to un-designate them if a project does not go ahead.
## **Free Reserves**
Breast Cancer UK is committed to a programme of activity that meets our charitable objectives. Given the uncertain nature of legacies, budgets are prepared on the assumption that only in cases where we have already been formally notified, are they included in income.
As a result, sudden large legacies or donations that are received during the financial year can result in reserves being held that are more than Breast Cancer UK’s reserves policy (free reserves) after allowing for designated funds.
To help us address this, our business plans now include a priority list of research and education projects which align with our strategic priorities and the impact that we want to achieve. Thus, excess legacies or unexpectedly large donations will be directed promptly to these projects.
26
## **Authority, Monitoring and Reporting**
Ongoing monitoring of the reserves is undertaken during the year by the CEO, Finance Manager and Finance Trustee. At the time mid-year financial results are available when budgets are revisited, the reserve position including how funds are allocated should be reported to the Audit, Risk and Scrutiny Committee meeting and the Board.
## **Reserve Policy Review**
The Reserves Policy will be reviewed annually by the Audit, Risk and Scrutiny Committee in February and approved by the Board of Trustees in March reviewing in detail the reserve position and taking into account prevailing conditions in the charity sector and short-term and medium-term plans for the charity.
At the Board meeting of 1 December 2020, Trustees determined to revisit the amount in emergency reserves in light of the reduction in staff numbers. Trustees resolved that £160,000 should be held in emergency reserve. This represents 6 months of expenditure. The total reserve level is sufficient to allow for the financial implications of a downturn in income or the need to significantly increase operational expenditure.
Excess Free Reserves at year end of 2020/21 amounted to £491,801. While we were pleased to find that the anticipated negative impact on income from the pandemic did not eventuate, with marked improvements in income in the second half of the year, we recognised the continued uncertainty and thus maintained a precautionary approach to ensure we can weather the storm of the pandemic and the financial crisis ahead.
## **Results and closing position**
The charity’s income exceeded expenditure this year by £311,467. This surplus was a welcome result of our tightened financial planning, reduced expenditure which was under budget by £126,866 and reformulated income generation approaches. Total income exceeded our annual budget by £259,415 including legacy and grants.
Given our initial projection of £74,814 deficit at 2020/21-year end, our closing position remains stable and is stronger than anticipated ensuring we enter the unpredictable year ahead with confidence to weather the storm.
27
## Structure Governance and Management
## **Structure**
Breast Cancer UK is a charitable company limited by guarantee (registration number 07348408), registered on the 8th November 2010 and registered as a charity on the 15th August 2001 (registered charity number 1138866). The company was established under the Memorandum of Association, which established the objects and powers of the charitable company. In the event of the company being wound up, members are required to contribute an amount not exceeding £10.
Our charitable objectives are as follows:
1. to advance health and save lives by encouraging a preventative approach to breast cancer.
2. to educate and raise awareness of the preventable risk factors for breast cancer and provide practical information to help people reduce their risk; and
3. to support scientific research that helps us to understand and address the preventable risk factors for breast cancer;
## **Governance**
The Directors of the Company, who are listed on the last page of this report are also charity trustees for the purposes of charity law and under the Company’s articles are known as members of the Board of Trustees.
All members of the Board of Trustees give their time voluntarily and receive no benefits from the charity. Any expenses reclaimed from the charity are set out in note 3 to the accounts. Several trustees have suffered from breast cancer or are close to people who have suffered from the disease. They use their own experience in this area to assist the charity.
In recruiting Trustees, the members seek to ensure the charity benefits from a broad range of different skills and expertise. Skills and expertise represented on the board include science and policy, medicine, cancer services, governance, law, accountancy, fundraising, PR, business management and IT. In the event of skills or individuals being lost due to retirements or resignations, the charity advertises for specific skills and interviews are carried out to ensure the most appropriate appointments are made.
This year we were sad to say goodbye to Mary Davis. After a number of years with the charity, Mary stood down from her position as Chair of the Board of the charity at the end of her term. The Board of Trustees unanimously agreed to appoint Wendy Clark, having already served two years as Trustees, as the Chair of the Board on 1 December 2020. We welcome three new trustees, Mark Jarvis, Sharon Nash and Margot Black to the board.
**----- Start of picture text -----**
Board of Trustees
Remuneration and
Audit Risk and
Appointments Science Committee
Committee Scrutiny Committee
**----- End of picture text -----**
28
## **Staff**
Breast Cancer UK’s staff are our greatest asset and we are committed to supporting every employee to achieve their potential and achieve personal goals which in turn will assist the organisation to achieve its objectives. Sadly, the uncertainty brought about by the COVID pandemic meant that we were forced to find cost savings through reducing our staff compliment. Following a redundancy consultation process in mid-2020, three roles were identified for redundancy: Head of Communications and Campaigns, Head of Fundraising and Development and Ambassador Programme Manager. This change resulted in a flattened hierarchy of roles and a reinforcement of cross team collaboration.
**----- Start of picture text -----**
CEO (FT)
Digital Content &
Finance Manager (FT) Communications Public Affairs Manager (0.6 Fundraising Head of Science and Research
Manager (FT) Officer (FT)
FTE) (0.8 FTE)
Community Scientific
Fundraising Research Officer
Officer (0.5 FTE) (FT)
**----- End of picture text -----**
This year we undertook a review of our staff performance appraisal processes to incentivise staff performance and ensure staff can grow and evolve professionally. A discretionary performance based indexation will be introduced in FY2122. In March the board approved a consolidated pay award of 1% in line with our Remuneration Policy.
## **Risk Management**
A risk register is established. Risk management sits with the CEO and ownership sits with specific Committees and the Board. The Committees of the Board of Trustees and the Board itself reviews the Risk Register at each meeting and it is updated regularly. Mitigating actions are considered and reviewed regularly. All policies and processes are under rolling review to ensure we are compliant with regulation.
## **Statement of public benefit**
The Trustees confirm that they have complied with the duty in Section 17 of the Charities Act 2011 to have regard to the Charity Commission’s General Guidance on public benefit.
Our charitable objectives are enshrined in our Memorandum of Association and Trustees to ensure that the charity’s activities are carried out for the public benefit. In July, these articles were formally amended with a special resolution passed to amend our ‘objects’ clause through our three new strategic approaches:
29
- to advance health and save lives by encouraging a preventative approach to breast cancer
- to educate and raise awareness of the preventable risk factors for breast cancer and provide practical information to help people reduce their risk
- to support scientific research that helps us to understand and address the preventable risk factors for breast cancer.
This report allows us to show how our charitable funds are spent and the impact that this has on those that access our information or use our services, as well as on the wider challenge to reduce breast cancer incidence rates.
By Order of the Board
Wendy Clark (Chair and Director of the Board of Trustees)
## **Breast Cancer UK Limited**
30
## Statement of Trustees Responsibilities for the Year Ended 31 March 2021
The trustees (who are also the directors of Breast Cancer UK Limited for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to
- select suitable accounting policies and then apply them consistently
- observe the methods and principles in the Charity SORP
- make judgements and estimates that are reasonable and prudent
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.
The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.
31
## **REGISTERED COMPANY NUMBER: 07348408 (England and Wales) REGISTERED CHARITY NUMBER: 1138866**
## **Report of the Trustees and**
**Unaudited Financial Statements for the Year Ended 31 March 2021**
## **for**
## **Breast Cancer UK Limited**
George Hay Partnership LLP Chartered Accountants St George's House George Street Huntingdon Cambridgeshire PE29 3GH
**Breast Cancer UK Limited**
## **Contents of the Financial Statements for the Year Ended 31 March 2021**
||**Page**|
|---|---|
|**Report of the Trustees**|2|
|**Independent Examiner's Report**|3|
|**Statement of Financial Activities**|4|
|**Balance Sheet**|5 to 6|
|**Cash Flow Statement**|7|
|**Notes to the Cash Flow Statement**|8|
|**Notes to the Financial Statements**|9 to 19|
|**Detailed Statement of Financial Activities**|20 to 21|
## **Breast Cancer UK Limited**
## **Report of the Trustees for the Year Ended 31 March 2021**
The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 March 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
## **STRUCTURE, GOVERNANCE AND MANAGEMENT**
## **Governing document**
The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.
## **REFERENCE AND ADMINISTRATIVE DETAILS**
**Registered Company number** 07348408 (England and Wales)
**Registered Charity number** 1138866
**Registered office** St. George's House, 14 George Street, Huntingdon, Cambridgeshire, PE29 3GH
## **Trustees**
Dr A S Giles Mrs R E Freeborough Miss E J Kendall Mrs M G Davies (resigned 30.11.20) Ms W Clark Dr N Taske Mrs O Otukoya Ms S R Nash (appointed 7.4.20) Mr M Jarvis (appointed 7.4.20) Ms M H Black (appointed 9.4.20) Dr B Stordal (appointed 17.6.21) Dr A Kakavouli (resigned 17.6.21) Mrs E M Mackeggie Gurney (resigned 9.4.20) Dr L Teixeira (resigned 2.7.20) Mrs J G M Tolentino-Deludet
## **Independent Examiner**
George Hay Partnership LLP, Chartered Accountants St George's House, George Street, Huntingdon, Cambridgeshire, PE29 3GH
Approved by order of the board of trustees on .24th December 2021 and signed on its behalf by:
Mrs R E Freeborough Deputy Chair of Trustees
Page 2
## **Independent Examiner's Report to the Trustees of Breast Cancer UK Limited**
## **Independent examiner's report to the trustees of Breast Cancer UK Limited ('the Company')**
I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2021.
## **Responsibilities and basis of report**
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.
## **Independent examiner's statement**
Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Mrs Toni Hunter FCCA ACA DChA George Hay Partnership LLP, Chartered Accountants St George's House George Street Huntingdon Cambridgeshire PE29 3GH
Date: 28[th] December 2021
Page 3
## **Breast Cancer UK Limited**
## **Statement of Financial Activities for the Year Ended 31 March 2021**
|Unrestricted
funds
Notes
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
2
595,891
Investment income
3
2,835
Other income
46,189
**Total**
644,915
**EXPENDITURE ON**
Raising funds
4
97,314
**Charitable activities**
5
Campaign costs
89,161
Education costs
93,570
Science costs
77,438
Governance costs
5,289
**Total**
362,772
**NET INCOME/(EXPENDITURE)**
282,143
**RECONCILIATION OF FUNDS**
**Total funds brought forward**
387,767
**TOTAL FUNDS CARRIED FORWARD**
669,910|Restricted
funds
£
68,079
-
-
68,079
-
-
38,755
-
-
38,755
29,324
(47,433)
(18,109)|2021
Total
funds
£
663,970
2,835
46,189
712,994
97,314
89,161
132,325
77,438
5,289
401,527
311,467
340,334
651,801|2020
Total
funds
£
397,846
4,050
-
401,896
90,961
116,867
132,970
125,684
7,523
474,005
(72,109)
412,443
340,334|
|---|---|---|---|
The notes form part of these financial statements
Page 4
## **Breast Cancer UK Limited**
Registered Company number 07348408 (England and Wales)
## **Balance Sheet 31 March 2021**
|Unrestricted
funds
Notes
£
**CURRENT ASSETS**
Debtors
11
13,793
Cash at bank and in hand
719,178
732,971
**CREDITORS**
Amounts falling due within one year
12
(54,389)
**NET CURRENT ASSETS/(LIABILITIES)**
678,582
**TOTAL ASSETS LESS CURRENT LIABILITIES**
678,582
**CREDITORS**
Amounts falling due after more than one year
13
(8,672)
**NET ASSETS**
669,910
**FUNDS**
15
Unrestricted funds
Restricted funds
**TOTAL FUNDS**|Restricted
funds
£
15,000
6,371
21,371
(39,480)
(18,109)
(18,109)
-
(18,109)|2021
Total
funds
£
28,793
725,549
754,342
(93,869)
660,473
660,473
(8,672)
651,801
669,910
(18,109)
651,801|2020
Total
funds
£
7,877
442,163
450,040
(60,168)
389,872
389,872
(49,538)
340,334
387,767
(47,433)
340,334|
|---|---|---|---|
The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2021.
The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2021 in accordance with Section 476 of the Companies Act 2006.
The notes form part of these financial statements
continued...
Page 5
## **Breast Cancer UK Limited**
Registered Company number 07348408 (England and Wales)
## **Balance Sheet - continued 31 March 2021**
The trustees acknowledge their responsibilities for
- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.
These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.
The financial statements were approved by the Board of Trustees and authorised for issue on 24th December 2021 and were signed on its behalf by:
Mrs R E Freeborough Deputy Chair of Trustees
The notes form part of these financial statements
Page 6
## **Breast Cancer UK Limited**
## **Cash Flow Statement for the Year Ended 31 March 2021**
|Notes
**Cash flows from operating activities**
Cash generated from operations
1
Net cash provided by/(used in) operating activities
**Cash flows from investing activities**
Interest received
Net cash provided by investing activities
**Change in cash and cash equivalents in the**
**reporting period**
**Cash and cash equivalents at the beginning**
**of the reporting period**
2
**Cash and cash equivalents at the end of**
**the reporting period**
2|2021
£
280,551
280,551
2,835
2,835
283,386
442,163
725,549|2020
£
(95,082)
(95,082)
4,050
4,050
(91,032)
533,195
442,163|
|---|---|---|
The notes form part of these financial statements
Page 7
## **Breast Cancer UK Limited**
## **Notes to the Cash Flow Statement for the Year Ended 31 March 2021**
|**1.**|**RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM**|**RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM**|**OPERATING**|**ACTIVITIES**|
|---|---|---|---|---|
||||2021|2020|
||||£|£|
||**Net income/(expenditure) for the reporting period (as per the**||||
||**Statement of Financial Activities)**||311,467|(72,109)|
||**Adjustments for:**||||
||Interest received||(2,835)|
(4,050)|
||(Increase)/decrease in debtors||(20,916)|
1,209|
||Decrease in creditors||(7,165)|(20,132)|
||**Net cash provided by/(used in) operations**||280,551|(95,082)|
|**2.**|**ANALYSIS OF CASH AND CASH EQUIVALENTS**||||
||||2021|2020|
||||£|£|
||Cash in hand||107|17|
||Notice deposits (less than 3 months)||725,442|442,146|
||Total cash and cash equivalents||725,549|442,163|
|3.|**ANALYSIS OF CHANGES IN NET FUNDS**||||
|||At 1.4.20|Cash flow|At 31.3.21|
|||£|£|£|
||**Net cash**||||
||Cash at bank and in hand|442,163|283,386|725,549|
||**Total**|442,163|283,386|725,549|
The notes form part of these financial statements
Page 8
**Breast Cancer UK Limited**
## **Notes to the Financial Statements for the Year Ended 31 March 2021**
## **1. ACCOUNTING POLICIES**
## **Basis of preparing the financial statements**
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
## **Income**
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.
## **Expenditure**
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.
## **Tangible fixed assets**
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 33% on cost
The charity operates a capitalisation policy of £500, meaning that any expenditure below this threshold is charged to the Statement of Financial Affairs as an expense.
## **Taxation**
The charity is exempt from corporation tax on its charitable activities.
## **Fund accounting**
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.
Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.
Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.
## **Pension costs and other post-retirement benefits**
The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.
continued...
Page 9
## **Breast Cancer UK Limited**
## **Notes to the Financial Statements - continued for the Year Ended 31 March 2021**
## **2. DONATIONS AND LEGACIES**
|Donations
Legacies
Grants
Grants received, included in the above, are as follows:
Other grants
**3.**
**INVESTMENT INCOME**
Deposit account interest
**4.**
**RAISING FUNDS**
**Raising donations and legacies**
Staff costs
Consultancy fees
Promotional activities
Subscriptions
Telephone
Printing, postage and stationery
Sundries
Donor entry fees
Donor platform fees|2021
£
502,219
111,751
50,000
663,970
2021
£
50,000
2021
£
2,835
2021
£
64,948
2,114
10,433
3,529
558
1,013
1,706
1,550
11,463
97,314|2020
£
328,685
69,161
-
397,846
2020
£
-
2020
£
4,050
2020
£
67,604
-
8,937
1,212
303
1,156
3,070
4,895
3,784
90,961|
|---|---|---|
||||
continued...
Page 10
## **Breast Cancer UK Limited**
## **Notes to the Financial Statements - continued for the Year Ended 31 March 2021**
## **5. CHARITABLE ACTIVITIES COSTS**
|**CHARITABLE ACTIVITIES COSTS**||||
|---|---|---|---|
|Campaign costs
Education costs
Science costs
Governance costs|Direct
Costs
£
67,577
110,747
55,204
-
233,528|Support
costs (see
note 6)
£
21,584
21,578
22,234
5,289
70,685|Totals
£
89,161
132,325
77,438
5,289|
||||304,213|
## **6. SUPPORT COSTS**
|**SUPPORT COSTS**||||
|---|---|---|---|
||||Information|
||Management||Finance|
||technology|||
||£|£|£|
|Campaign costs|1,926|25|898|
|Education costs|1,922|25|897|
|Science costs|1,980|26|925|
|Governance costs|-|-|-|
||5,828|76|2,720|
||Human|Governance||
||resources|costs|Totals|
||£|£|£|
|Campaign costs|18,735|-|21,584|
|Education costs|18,734|-|21,578|
|Science costs|19,303|-|22,234|
|Governance costs|-|5,289|5,289|
||56,772|5,289|70,685|
Activity Basis of allocation Management proportion of charitable activities Finance proportion of charitable activities Information technology proportion of charitable activities Human resources proportion of charitable activities Governance costs proportion of charitable activities
continued...
Page 11
## **Breast Cancer UK Limited**
## **Notes to the Financial Statements - continued for the Year Ended 31 March 2021**
## **6. SUPPORT COSTS - continued**
Support costs, included in the above, are as follows:
|**Management**
Campaign
Education
costs
costs
£
£
Insurance
339
339
Telephone
136
135
Postage and stationery
206
205
Sundries
488
488
Consultancy
230
229
Travel and accommodation
-
-
Subscriptions
527
526
1,926
1,922
**Finance**
Campaign
Education
costs
costs
£
£
Bank charges
25
25
**Information technology**
Campaign
Education
costs
costs
£
£
Website and IT costs
898
897
**Human resources**
Campaign
Education
costs
costs
£
£
Salaries
17,002
17,003
Social security
1,165
1,164
Pensions
523
522
Training
36
36
Staff related costs
9
9
18,735
18,734|2021
2020
Science
Total
Total
costs
activities
activities
£
£
£
349
1,027
1,008
139
410
180
211
622
762
503
1,479
1,560
236
695
-
-
-
9,801
542
1,595
710
1,980
5,828
14,021
2021
2020
Science
Total
Total
costs
activities
activities
£
£
£
26
76
16
2021
2020
Science
Total
Total
costs
activities
activities
£
£
£
925
2,720
6,028
2021
2020
Science
Total
Total
costs
activities
activities
£
£
£
17,518
51,523
36,387
1,200
3,529
3,187
538
1,583
1,328
37
109
1,148
10
28
354
19,303
56,772
42,404|
|---|---|
continued...
Page 12
## **Breast Cancer UK Limited**
## **Notes to the Financial Statements - continued for the Year Ended 31 March 2021**
## **6. SUPPORT COSTS - continued**
|**SUPPORT COSTS - continued**||||
|---|---|---|---|
|**Governance costs**|2021|
2020||
|||Governance|Total|
|||costs|activities|
|||£|£|
|Trustees' expenses||-|664|
|Trustees' meetings and training||636|3,739|
|Accountancy fees||3,901|3,120|
|Legal fees||752|-|
|||5,289|7,523|
## **7. TRUSTEES' REMUNERATION AND BENEFITS**
There were no trustees' remuneration or other benefits for the year ended 31 March 2021 nor for the year ended 31 March 2020.
|**Trustees' expenses**
Trustees' expenses
**8.**
**STAFF COSTS**
Wages and salaries
Social security costs
Other pension costs
The average monthly number of employees during the year was as follows:
Management and administration
Fundraising
Campaigns, Science and Education|2021
£
-
2021
£
265,091
20,398
9,027
294,516
2021
1
2
7
10|2020
£
664
2020
£
276,822
24,631
8,286
309,739
2020
1
2
7
10|
|---|---|---|
||||
No employees received emoluments in excess of £60,000.
continued...
Page 13
## **Breast Cancer UK Limited**
## **Notes to the Financial Statements - continued for the Year Ended 31 March 2021**
## **9. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**
|Unrestricted
funds
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
365,645
Investment income
4,050
**Total**
369,695
**EXPENDITURE ON**
Raising funds
90,961
**Charitable activities**
Campaign costs
116,867
Education costs
128,970
Science costs
100,684
Governance costs
7,523
**Total**
445,005
**NET INCOME/(EXPENDITURE)**
(75,310)
**RECONCILIATION OF FUNDS**
**Total funds brought forward**
463,077
**TOTAL FUNDS CARRIED FORWARD**
387,767|Restricted
funds
£
32,201
-
32,201
-
-
4,000
25,000
-
29,000
3,201
(50,634)
(47,433)|Total
funds
£
397,846
4,050
401,896
90,961
116,867
132,970
125,684
7,523
474,005
(72,109)
412,443
340,334|
|---|---|---|
continued...
Page 14
|**Breast Cancer UK Limited**
**Notes to the Financial Statements - continued**
**for the Year Ended 31 March 2021**
**10.**
**TANGIBLE FIXED ASSETS**
**COST**
At 1 April 2020
Disposals
At 31 March 2021
**DEPRECIATION**
At 1 April 2020
Eliminated on disposal
At 31 March 2021
**NET BOOK VALUE**
At 31 March 2021
At 31 March 2020
**11.**
**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Monies owed
Gift aid debtor
Prepayments
**12.**
**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Trade creditors
Social security and other taxes
Accruals
Grants payable||Computer
equipment
£
3,721
(3,721)
-
3,721
(3,721)
-
-
-
2021
2020
£
£
169
50
27,266
6,730
1,358
1,097
28,793
7,877
2021
2020
£
£
21,982
1,346
-
108
4,568
3,120
67,319
55,594
93,869
60,169|
|---|---|---|
||||
continued...
Page 15
## **Breast Cancer UK Limited**
## **Notes to the Financial Statements - continued for the Year Ended 31 March 2021**
## **13. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR**
|Deferred grants
**14.**
**MOVEMENT IN FUNDS**
Net
movement
At 1.4.20
in funds
£
£
**Unrestricted funds**
General Fund
354,635
282,143
Website Development Fund
8,492
-
Science Grant Budget
24,640
-
387,767
282,143
**Restricted funds**
Breast Density Research Project
(20,787)
16,041
Oxysterols project
(26,646)
2,038
Digital Learning Tool
-
11,245
(47,433)
29,324
**TOTAL FUNDS**
340,334
311,467
Net movement in funds, included in the above are as follows:
Incoming
resources
£
**Unrestricted funds**
General Fund
644,915
**Restricted funds**
Breast Density Research Project
16,041
Oxysterols project
2,038
Digital Learning Tool
50,000
68,079
**TOTAL FUNDS**
712,994|2021
2020
£
£
8,672
49,538
Transfers
between
At
funds
31.3.21
£
£
(66,868)
569,910
(8,492)
-
75,360
100,000
-
669,910
-
(4,746)
-
(24,608)
-
11,245
-
(18,109)
-
651,801
Resources
Movement
expended
in funds
£
£
(362,772)
282,143
-
16,041
-
2,038
(38,755)
11,245
(38,755)
29,324
(401,527)
311,467|
|---|---|
continued...
Page 16
## **Breast Cancer UK Limited**
## **Notes to the Financial Statements - continued for the Year Ended 31 March 2021**
## **14. MOVEMENT IN FUNDS - continued**
## **Comparatives for movement in funds**
|**Unrestricted funds**
General Fund
Website Development Fund
Science Grant Budget
**Restricted funds**
Breast Density Research Project
Funding for Ambassador Training
Oxysterols project
**TOTAL FUNDS**
Comparative net movement in funds, included in the above are as
**Unrestricted funds**
General Fund
Website Development Fund
Science Grant Budget
**Restricted funds**
Breast Density Research Project
Funding for Ambassador Training
Oxysterols project
Breast Chip Research
**TOTAL FUNDS**|Net
movement
At
At 1.4.19
in funds
31.3.20
£
£
£
383,077
(28,442)
354,635
35,000
(26,508)
8,492
45,000
(20,360)
24,640
463,077
(75,310)
387,767
(26,328)
5,541
(20,787)
4,000
(4,000)
-
(28,306)
1,660
(26,646)
(50,634)
3,201
(47,433)
412,443
(72,109)
340,334
follows:
Incoming
Resources
Movement
resources
expended
in funds
£
£
£
369,695
(398,137)
(28,442)
-
(26,508)
(26,508)
-
(20,360)
(20,360)
369,695
(445,005)
(75,310)
5,541
-
5,541
-
(4,000)
(4,000)
1,660
-
1,660
25,000
(25,000)
-
32,201
(29,000)
3,201
401,896
(474,005)
(72,109)|
|---|---|
continued...
Page 17
## **Breast Cancer UK Limited**
## **Notes to the Financial Statements - continued for the Year Ended 31 March 2021**
## **14. MOVEMENT IN FUNDS - continued**
A current year 12 months and prior year 12 months combined position is as follows:
|||Net|Transfers||
|---|---|---|---|---|
|||movement|between|At|
||At 1.4.19|in funds|funds|31.3.21|
||£|£|£|£|
|**Unrestricted funds**|||||
|General Fund|383,077|253,701|(66,868)|569,910|
|Website Development Fund|35,000|(26,508)|(8,492)|-|
|Science Grant Budget|45,000|(20,360)|75,360|100,000|
||463,077|206,833|-|669,910|
|**Restricted funds**|||||
|Breast Density Research Project|(26,328)|21,582|-|(4,746)|
|Funding for Ambassador Training|4,000|(4,000)|-|-|
|Oxysterols project|(28,306)|3,698|-|(24,608)|
|Digital Learning Tool|-|11,245|-|11,245|
||(50,634)|32,525|-|(18,109)|
|**TOTAL FUNDS**|412,443|239,358|-|651,801|
|A current year 12 months and prior year 12 months combined||net movement in funds, included||in the above|
|are as follows:|||||
|||Incoming|Resources|Movement|
|||resources|expended|in funds|
|||£|£|£|
|**Unrestricted funds**|||||
|General Fund||1,014,610|(760,909)|253,701|
|Website Development Fund||-|(26,508)|(26,508)|
|Science Grant Budget||-|(20,360)|(20,360)|
|||1,014,610|(807,777)|206,833|
|**Restricted funds**|||||
|Breast Density Research Project||21,582|-|21,582|
|Funding for Ambassador Training||-|(4,000)|(4,000)|
|Oxysterols project||3,698|-|3,698|
|Breast Chip Research||25,000|(25,000)|-|
|Digital Learning Tool||50,000|(38,755)|11,245|
|||100,280|(67,755)|32,525|
|**TOTAL FUNDS**||1,114,890|(875,532)|239,358|
Page 18
## **Breast Cancer UK Limited**
**Notes to the Financial Statements - continued for the Year Ended 31 March 2021**
## **16. RELATED PARTY DISCLOSURES**
There were no related party transactions for the year ended 31 March 2021.
Page 19
## **Breast Cancer UK Limited**
## **Detailed Statement of Financial Activities for the Year Ended 31 March 2021**
|**INCOME AND ENDOWMENTS**
**Donations and legacies**
Donations
Legacies
Grants
**Investment income**
Deposit account interest
**Other income**
Government Grants
**Total incoming resources**
**EXPENDITURE**
**Raising donations and legacies**
Salaries
Social security
Pensions
Consultancy fees
Promotional activities
Subscriptions
Telephone
Printing, postage and stationery
Sundries
Donor entry fees
Donor platform fees
**Charitable activities**
Campaign, Science and Education salaries
Campaign, Science and Education social security
Campaign, Science and Education pensions
Telephone
Postage and stationery
Advertising
Science grants
Website and software costs
Subscriptions
Literature design and print
Travel
Carried forward|2021
£
502,219
111,751
50,000
663,970
2,835
46,189
712,994
58,663
3,823
2,462
2,114
10,433
3,529
558
1,013
1,706
1,550
11,463
97,314
154,905
13,046
4,982
973
22
-
-
4,640
591
1,724
-
180,883|2020
£
328,685
69,161
-|
|---|---|---|
|||397,846
4,050
-|
|||401,896
60,825
5,015
1,764
-
8,937
1,212
303
1,156
3,070
4,895
3,784|
|||90,961
179,610
16,429
5,194
334
13
25
45,360
20,776
1,727
1,969
1,364
272,801|
This page does not form part of the statutory financial statements
Page 20
## **Breast Cancer UK Limited**
## **Detailed Statement of Financial Activities for the Year Ended 31 March 2021**
|**Charitable activities**
Brought forward
Consultants
Exhibitions and conferences
Ambassador project
Recruitment and Training Costs
Digital learning tool
**Support costs**
**Management**
Insurance
Telephone
Postage and stationery
Sundries
Consultancy
Travel and accommodation
Subscriptions
**Finance**
Bank charges
**Information technology**
Website and IT costs
**Human resources**
Salaries
Social security
Pensions
Training
Staff related costs
**Governance costs**
Trustees' expenses
Trustees' meetings and training
Accountancy fees
Legal fees
Total resources expended
**Net income/(expenditure)**|2021
£
180,883
1,849
-
11,801
240
38,755
233,528
1,027
410
622
1,479
695
-
1,595
5,828
76
2,720
51,523
3,529
1,583
109
28
56,772
-
636
3,888
765
5,289
401,527
311,467|2020
£
272,801
-
874
36,770
2,607
-
313,052
1,008
180
762
1,560
-
9,801
710
14,021
16
6,028
36,387
3,187
1,328
1,148
354
42,404
664
3,739
3,120
-
7,523
474,005
(72,109)|
|---|---|---|
This page does not form part of the statutory financial statements
Page 21